ReviewExperimental & molecular medicine2020
Stomach microbiota, Helicobacter pylori, and group 2 innate lymphoid cells.
Review in Experimental & molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Microbial dynamics in gastric cancer: insights from full-length 16S rRNA nanopore sequencing in the MAGIC cohort.Frontiers in microbiology · 2026Article
- Dendritic Cells and Their Crucial Role in Modulating Innate Lymphoid Cells for Treating and Preventing Infectious Diseases.Pathogens (Basel, Switzerland) · 2025Review
- Gut Microbiota in Women with Eating Disorders: A New Frontier in Pathophysiology and Treatment.Nutrients · 2025Review
- Do Gut Microbiomes Shift After Bariatric Surgery? A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Gut Microbiota: A New Challenge in Mood Disorder Research.Life (Basel, Switzerland) · 2025Review
- New perspectives on gastric disorders: the relationship between innate lymphoid cells and microbes in the stomach.Cellular and molecular life sciences : CMLS · 2025Review
- Diet, Gastric Microbiota, and Metabolites in Gastric Tumorigenesis.Research (Washington, D.C.) · 2025Review
- Microbial oncogenesis within the gastric niche: how the gastric microbiota influencesFrontiers in microbiology · 2025Review
- Microbiome influence in gastric cancer progression and therapeutic strategies.Frontiers in medicine · 2025Review
- Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.Journal of experimental & clinical cancer research : CR · 2024Review
- Review
- Review
- The Association between Dysbiosis and Neurological Conditions Often Manifesting with Chronic Pain.Biomedicines · 2023Review
- Gastric microbiota: an emerging player in gastric cancer.Frontiers in microbiology · 2023Review
- Gut Microbiota Host-Gene Interaction.International journal of molecular sciences · 2022Review
- Microbiome as an immune regulator in health, disease, and therapeutics.Advanced drug delivery reviews · 2022Review
- Review
- The Association Between the Gut Microbiome, Nutritional Habits, Antibiotics, and Gastric Cancer: a Scoping Review.Current nutrition reports · 2022Article
- Metaomics in Clinical Laboratory: Potential Driving Force for Innovative Disease Diagnosis.Frontiers in microbiology · 2022Review
- The interplay betweenFrontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The stomach has been thought to host few commensal bacteria because of the existence of barriers, such as gastric acid. However, recent culture-independent, sequencing-based microbial analysis has shown that the stomach also harbors a wide diversity of microbiota. Although the stomach immune system, especially innate lymphoid cells (ILCs), has not been well elucidated, recent studies have shown that group 2 ILCs (ILC2s) are the dominant subtype in the stomach of both humans and mice. Stomach ILC2s are unique in that their existence is dependent on stomach microbiota, in sharp contrast to the lack of an impact of commensal microbiota on ILC2s in other tissues. The microbiota dependency of stomach ILC2s is partly explained by their responsiveness to interleukin (IL)-7. Stomach ILC2s express significantly higher IL-7 receptor protein levels on their surface and proliferate more in response to IL-7 stimulation in vitro than small intestinal ILC2s. Consistently, the stomach expresses much higher IL-7 protein levels than the small intestine. IL-5 secreted from stomach ILC2s promotes immunoglobulin (Ig) A production by plasma B cells. In a murine model, stomach ILC2s are important in containing Helicobacter pylori infection, especially in the early phase of infection, by promoting IgA production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.